Publishing: May 2021 | Report Code: LS10155 | Available Format: PDF
The pompe disease market is growing at a significant rate mainly due to special provisions for orphan drugs. Regulatory assistance in emerging nations is one of the major trends seen in the pompe disease market.
Pompe disease is a type of lysergic acid diethylamide (LSD). LSD refers to a group of diseases arising from the increase of specific substrates and is inherited autosomal recessive disorders. Lysergic acid diethylamide is progressive and having uneven age of onset and clinical symptoms. Pompe disease is a hereditary and repeatedly incurable disorder caused by lack of acid alpha glucosidase, an enzyme desired to split down glycogen in particular structures of our body. Patients having pompe disease have little amount of or no acid alpha glucosidase enzyme activity, so break down of glycogen is not possible. The additional glycogen builds up in the patient and is stored in skeletal muscle, heart and other tissues, which causes the progressive indications of pompe disease. Increase of glycogen in certain organs and tissues restraints normal functions of patient’s organs. Pompe disease is also known by other names such as glycogen storage disease type II, acid maltase deficiency, lysosomal alpha-glucosidase deficiency, acid alpha-glucosidase deficiency and glycogenosis type II.
Pompe disease is categorized into two broad categories as adult-onset pompe disease and infantile onset pompe disease. Both the parents pass on one strangely altered copy of the gene to their child. A parent with an altered copy of the gene is known as a carrier and the disease can affect both men and women irrespective of the gender. The disease is acquired by the individuals at the time of birth only, but the onset of indications differs significantly. The researchers have identified more than 300 genetic mutations that can cause pompe disease. Enzyme replacement therapy and diet therapy are useful in dropping the clinical demonstrations of the disease.
Pompe disease is an unusual condition and has an occurrence rate of approximately 1 patient in 38,000 and 1 child in 2,50,000 live births globally. If an infant catch the disease, which is caused by a deficiency of acid alpha-glucosidase enzyme, the survival rate of the infant is expected to be 26%.
Pompe disease treatment has a major role in terms of the limited number of treatment options available for late stages of pompe disease and also for early stage of pompe disease. Even though estrogen replacement therapy (ERT) is approved for the treatment of pompe disease, but still there are physician concerns about efficacy, safety and tolerability. The symptoms of pompe disease are unspecific and thus difficult to diagnose accurately.
The competition in the pompe disease market is mainly weak, and the market is served by the two estrogen replacement therapy drugs available in the market namely Myozyme for infants and Lumizyme for adults. Both the drugs are permitted for different subclasses of Pompe disease. Gene therapy for the treatment of pompe disease is presently under study; however, its advancement is in a preclinical stage. Dietary treatment for pompe disease has also been described and it is under study.
Government regulations, such as orphan drug exclusivity and limited patient population are the factors restraining the growth of the pompe disease market.
Some of the competitors in the market are Genzyme Corporation, EpiVax, Inc., Amicus Therapeutics, Audentes Therapeutics, BioMarin Pharmaceutical Inc., Valerion Therapeutics, LLC, Oxyrane, and Sangamo BioSciences Inc.
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws